IS8304A - Kínólín- og kínasólínafleiður með sækni í viðtaka af gerð 5HT1 - Google Patents

Kínólín- og kínasólínafleiður með sækni í viðtaka af gerð 5HT1

Info

Publication number
IS8304A
IS8304A IS8304A IS8304A IS8304A IS 8304 A IS8304 A IS 8304A IS 8304 A IS8304 A IS 8304A IS 8304 A IS8304 A IS 8304A IS 8304 A IS8304 A IS 8304A
Authority
IS
Iceland
Prior art keywords
quinoline
receptors
affinity
type
quinazoline derivatives
Prior art date
Application number
IS8304A
Other languages
English (en)
Other versions
IS2744B (is
Inventor
Bergauer Markus
Bertani Barbara
Biagetti Matteo
Mark Bromidge Steven
Falchi Alessandro
Philip Leslie Colin
Merlo Giancarlo
Antonia Pizzi Domenica
Rinaldi Marilisa
Piero Stasi Luigi
Tibasco Jessica
Kouk Keong Vong Antonio
Edward Simon
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS8304A publication Critical patent/IS8304A/is
Publication of IS2744B publication Critical patent/IS2744B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IS8304A 2003-07-18 2006-02-15 Tæki til þess að öngla, ásamt möguleika til þess að beita línu IS2744B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0316915.8A GB0316915D0 (en) 2003-07-18 2003-07-18 Compounds
PCT/EP2004/008000 WO2005014552A1 (en) 2003-07-18 2004-07-15 Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors

Publications (2)

Publication Number Publication Date
IS8304A true IS8304A (is) 2006-02-15
IS2744B IS2744B (is) 2011-08-15

Family

ID=27764115

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8304A IS2744B (is) 2003-07-18 2006-02-15 Tæki til þess að öngla, ásamt möguleika til þess að beita línu

Country Status (28)

Country Link
US (5) US7279481B2 (is)
EP (3) EP1876174B1 (is)
JP (1) JP2006528146A (is)
KR (1) KR20060041242A (is)
CN (1) CN100441571C (is)
AR (1) AR046394A1 (is)
AT (2) ATE448205T1 (is)
AU (1) AU2004263268B2 (is)
BR (1) BRPI0412695A (is)
CA (1) CA2532452A1 (is)
CY (1) CY1107974T1 (is)
DE (2) DE602004012564T2 (is)
DK (1) DK1646613T3 (is)
ES (2) ES2336148T3 (is)
GB (1) GB0316915D0 (is)
HR (1) HRP20080226T3 (is)
IL (1) IL173036A0 (is)
IS (1) IS2744B (is)
MA (1) MA27926A1 (is)
MX (1) MXPA06000716A (is)
NO (1) NO20060774L (is)
NZ (1) NZ544586A (is)
PL (1) PL1646613T3 (is)
PT (1) PT1646613E (is)
RU (1) RU2402533C2 (is)
SI (1) SI1646613T1 (is)
TW (1) TW200521115A (is)
WO (1) WO2005014552A1 (is)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1408976T5 (da) 2001-07-20 2011-01-10 Psychogenics Inc Behandling af ADHD (Attention deficit hyperactivity disorder)
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
MXPA06014495A (es) * 2004-06-17 2007-03-01 Cytokinetics Inc Compuestos, composiciones y metodos.
KR100817538B1 (ko) * 2006-07-05 2008-03-27 한국화학연구원 신규 치환된―１ｈ―퀴나졸린―２,４―디온 유도체, 이의제조방법 및 이를 함유하는 약학적 조성물
MX2009006672A (es) * 2006-12-19 2009-10-26 Univ Virginia Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol.
WO2008095086A2 (en) * 2007-01-31 2008-08-07 University Of Virginia Patent Foundation Topiramate plus naltrexone for the treatment of addictive disorders
DE602007012683D1 (de) 2007-07-19 2011-04-07 Esteve Labor Dr Substituierte Tetrahydro-Chinolinsulfonamidverbindungen, ihre Herstellung und ihre Verwendung als Medikamente
WO2009029308A1 (en) * 2007-08-27 2009-03-05 University Of Virginia Patent Foundation Medication combinations for the treatment of alcoholism and drug addiction
NZ588037A (en) 2008-02-28 2012-08-31 Univ Virginia Patent Found Serotonin transporter gene SLC6A4 and treatment of alcoholism
US8871753B2 (en) 2008-04-24 2014-10-28 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
EP2298199B1 (en) * 2008-05-06 2012-05-23 Biedermann Technologies GmbH & Co. KG Rod-shaped implant, in particular for the dynamic stabilization of the spine
US20100298397A1 (en) * 2009-05-19 2010-11-25 Singh Nikhilesh N Method of treatment of obsessive compulsive disorder with ondansetron
CN101671336B (zh) 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
EP2308850A1 (en) * 2009-10-06 2011-04-13 Laboratorios Del. Dr. Esteve, S.A. Heterocycyl-substituted-alkylamino phenyl derivatives, their preparation and use as medicaments
SI2801625T1 (en) 2010-07-02 2018-04-30 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug addiction
CN103842332B (zh) 2011-08-09 2016-08-17 武田药品工业株式会社 环丙胺化合物
US20130096173A1 (en) 2011-09-09 2013-04-18 Bankole A. Johnson Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
EP2847193B1 (en) * 2012-05-09 2019-08-07 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
CN103508927A (zh) * 2012-06-25 2014-01-15 天津药物研究院 一种2-甲磺酰氨基二苯醚的制备方法
WO2014058071A1 (ja) 2012-10-12 2014-04-17 武田薬品工業株式会社 シクロプロパンアミン化合物およびその用途
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
KR102305244B1 (ko) 2013-11-20 2021-09-27 우베 고산 가부시키가이샤 신규 3-아자비사이클로[3.1.0]헥산 유도체 및 그 의약 용도
PE20161441A1 (es) 2014-04-11 2017-01-21 Takeda Pharmaceuticals Co Compuesto de ciclopropanamina y sus usos
FR3028527A1 (fr) 2014-11-13 2016-05-20 Pivert Identification de facteurs de transcription de yarrowia lipolytica
WO2016075314A1 (fr) 2014-11-13 2016-05-19 Institut National De La Recherche Agronomique Identification de facteurs de transcription de yarrowia lipolytica affectant la production de proteines
PL3193901T3 (pl) 2014-12-23 2018-10-31 4D Pharma Research Limited Polipeptyd pyrynowy i immunomodulacja
CN113862175A (zh) 2014-12-23 2021-12-31 4D制药研究有限公司 免疫调控
MD3206700T2 (ro) 2015-06-15 2019-12-31 4D Pharma Res Ltd Compoziții conținând tulpini bacteriene
PE20180267A1 (es) 2015-06-15 2018-02-06 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
RS59446B1 (sr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Blautia stercosis i wexlerae za upotrebu u lečenju inflamatornih i autoimunskih bolesti
WO2017085520A1 (en) 2015-11-20 2017-05-26 4D Pharma Research Limited Compositions comprising bacterial strains
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
JP6441536B2 (ja) 2016-03-04 2018-12-19 フォーディー ファーマ ピーエルシー４Ｄ Ｐｈａｒｍａ Ｐｌｃ 細菌株を含む組成物
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
HUE054164T2 (hu) 2017-05-22 2021-08-30 4D Pharma Res Ltd Baktériumtörzseket tartalmazó készítmények
WO2018215782A1 (en) 2017-05-24 2018-11-29 4D Pharma Research Limited Compositions comprising bacterial strain
SMT202000695T1 (it) 2017-06-14 2021-01-05 4D Pharma Res Limited Composizioni comprendenti ceppi batterici
LT3600363T (lt) 2017-06-14 2021-02-10 4D Pharma Research Limited Kompozicijos, apimančios bakterijų kamienus
MA49010B1 (fr) 2017-06-14 2020-11-30 4D Pharma Res Ltd Compositions comprenant une souche bactérienne du genre megasphaera et leurs utilisations
CN108047143A (zh) * 2017-12-18 2018-05-18 刘凤娟 一种用于治疗功能性胃肠病的5-羟色胺受体拮抗剂的合成方法
HRP20231253T1 (hr) 2018-06-27 2024-02-02 Bristol-Myers Squibb Company Supstituirani spojevi naftiridina korisni kao aktivatori t stanica
ES2950007T3 (es) 2018-06-27 2023-10-04 Bristol Myers Squibb Co Compuestos de naftiridinona útiles como activadores de células T
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
ES3038401T3 (en) 2019-12-23 2025-10-13 Bristol Myers Squibb Co Substituted quinazolinyl compounds useful as t cell activators
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
CN115175907B (zh) 2019-12-23 2024-08-02 百时美施贵宝公司 可用作t细胞激活剂的经取代的哌嗪衍生物
CN118308475B (zh) * 2024-03-18 2024-11-26 安徽医科大学第一附属医院 Htr1b作为胚胎发育停滞的诊断标志物和治疗靶点方面的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2641602A (en) 1950-11-29 1953-06-09 Eastman Kodak Co 1, 8-dihydroxy-5-nitro-4-hydroxyethylphenyl aminoanthraquinone compounds
US3937708A (en) * 1971-06-07 1976-02-10 Boehringer Ingelheim Gmbh N-phenyl-imidazolidine-1-ones
US3992537A (en) * 1971-06-07 1976-11-16 Boehringer Ingelheim Gmbh Pharmaceutical compositions containing an N-phenyl-imidazolidine-2-one and method of use
US3975525A (en) * 1971-06-07 1976-08-17 Boehringer Ingelheim Gmbh N-[4'-Imidazolidinon-(2)-yl-phenethyl]-N'-pyridyl-piperazines and salts thereof
JPS5883677A (ja) 1981-11-11 1983-05-19 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
US4891275A (en) * 1982-10-29 1990-01-02 Norsk Hydro A.S. Aluminum shapes coated with brazing material and process of coating
JPS6354363A (ja) 1986-08-26 1988-03-08 Ss Pharmaceut Co Ltd キノリン誘導体
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US4933447A (en) 1987-09-24 1990-06-12 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
US4891375A (en) * 1988-01-13 1990-01-02 Pfizer Inc. Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds
JP2777159B2 (ja) 1988-12-22 1998-07-16 エーザイ株式会社 環状アミン誘導体を含有する医薬
AU645681B2 (en) * 1991-05-02 1994-01-20 John Wyeth & Brother Limited Piperazine derivatives
NZ240863A (en) * 1991-09-11 1995-04-27 Mcneilab Inc Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof
GB9300195D0 (en) 1993-01-06 1993-03-03 Wyeth John & Brother Ltd Piperazine derivatives
GB9300194D0 (en) 1993-01-06 1993-03-03 Wyeth John & Brother Ltd Piperazine derivatives
GB9308725D0 (en) 1993-04-27 1993-06-09 Wyeth John & Brother Ltd Piperazine derivatives
ES2271967T3 (es) * 1996-03-29 2007-04-16 Duphar International Research B.V Compuestos de piperazina y piperidina.
AU2446297A (en) * 1996-04-30 1997-11-19 Warner-Lambert Company Substituted piperazines and piperidines as central nervous system agents
GB2312843A (en) 1996-05-07 1997-11-12 Merck & Co Inc Method of treating rheumatoid arthritis
WO1998025617A1 (en) 1996-12-13 1998-06-18 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
DE69819266T2 (de) * 1997-09-02 2004-07-29 Duphar International Research B.V. Piperidin- und Piperazin Derivate als 5-HT1-Rezeptor-Agonisten
EP0900792B1 (en) * 1997-09-02 2003-10-29 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists
JP4570773B2 (ja) * 1997-10-27 2010-10-27 ニューロサーチ、アクティーゼルスカブ ニコチン性アセチルコリンレセプターに於けるコリン作動性リガンドとしてのヘテロアリールジアザシクロアルカン
JP2002508366A (ja) * 1997-12-12 2002-03-19 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー キノリンピペラジンおよびキノリンピペリジン誘導体、それらの製造方法、ならびに複合的５−ｈｔ１ａ、５−ｈｔ１ｂおよび５−ｈｔ１ｄ受容体アンタゴニストとしてのそれらの用途
UA62015C2 (en) * 1998-12-28 2003-12-15 Pfizer Prod Inc Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants)
CA2341542A1 (en) 1999-06-24 2000-12-28 Toray Industries, Inc. .alpha.1b-adrenergic receptor antagonists
DE60017446T2 (de) * 1999-11-05 2006-03-02 Smithkline Beecham P.L.C., Brentford Isochinolin- und Chinazolinderivate mit kombinierter 5-HT1A-, 5-HT1B- und 5-HT1D- Rezeptoraffinität
JP4242643B2 (ja) 2000-10-26 2009-03-25 スミスクライン ビーチャム ピー エル シー ベンズオキサジノン誘導体、その製造および使用
CA2364211A1 (en) 2000-12-05 2002-06-05 Phillip Branch Chappell Combination treatment for depression, anxiety and psychosis
GB0106419D0 (en) * 2001-03-15 2001-05-02 Smithkline Beecham Plc Novel compounds
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
GB0203804D0 (en) 2002-02-18 2002-04-03 Glaxo Group Ltd Compounds
GB0224084D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
MXPA05004273A (es) 2002-11-08 2005-10-18 Warner Lambert Co Derivados de fenilalquil y piridilalquil piperazina.
GB0227240D0 (en) 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
US6759435B1 (en) * 2003-07-03 2004-07-06 A.P. Group Inc. Antidepressant drugs and methods
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
WO2005087742A1 (en) 2004-03-08 2005-09-22 Exelixis, Inc. Metabolic kinase modulators and methods of use as pesticides
KR20060130697A (ko) 2004-03-10 2006-12-19 알타나 파마 아게 신규한 아미도-치환 히드록시-6-페닐페난트리딘 및 ｐｄｅ4억제제로서의 이의 용도
PE20060653A1 (es) 2004-08-31 2006-09-27 Glaxo Group Ltd Derivados triciclicos condensados como moduladores del receptor 5-ht1

Also Published As

Publication number Publication date
HK1089438A1 (en) 2006-12-01
AR046394A1 (es) 2005-12-07
HRP20080226T3 (en) 2008-06-30
IL173036A0 (en) 2006-06-11
DE602004024141D1 (de) 2009-12-24
US20090312546A1 (en) 2009-12-17
NO20060774L (no) 2006-04-06
RU2006104993A (ru) 2006-08-10
MA27926A1 (fr) 2006-06-01
EP1876174B1 (en) 2009-11-11
CN1852896A (zh) 2006-10-25
CY1107974T1 (el) 2013-09-04
AU2004263268B2 (en) 2010-12-16
US20080280919A1 (en) 2008-11-13
GB0316915D0 (en) 2003-08-20
WO2005014552A1 (en) 2005-02-17
US20100204273A1 (en) 2010-08-12
SI1646613T1 (sl) 2008-08-31
ATE389637T1 (de) 2008-04-15
ES2302543T3 (es) 2008-07-16
US7459456B2 (en) 2008-12-02
EP1646613A1 (en) 2006-04-19
IS2744B (is) 2011-08-15
DE602004012564D1 (de) 2008-04-30
US7592346B2 (en) 2009-09-22
US20060229312A1 (en) 2006-10-12
DE602004012564T2 (de) 2009-04-30
PT1646613E (pt) 2008-06-19
RU2402533C2 (ru) 2010-10-27
EP2145622A1 (en) 2010-01-20
CN100441571C (zh) 2008-12-10
TW200521115A (en) 2005-07-01
DK1646613T3 (da) 2008-07-14
US20070167423A1 (en) 2007-07-19
US7279481B2 (en) 2007-10-09
ATE448205T1 (de) 2009-11-15
US7732600B2 (en) 2010-06-08
KR20060041242A (ko) 2006-05-11
JP2006528146A (ja) 2006-12-14
AU2004263268A1 (en) 2005-02-17
EP1646613B1 (en) 2008-03-19
CA2532452A1 (en) 2005-02-17
MXPA06000716A (es) 2006-03-30
BRPI0412695A (pt) 2006-10-03
NZ544586A (en) 2009-05-31
ES2336148T3 (es) 2010-04-08
PL1646613T3 (pl) 2008-08-29
EP1876174A1 (en) 2008-01-09

Similar Documents

Publication Publication Date Title
IS8304A (is) Kínólín- og kínasólínafleiður með sækni í viðtaka af gerð 5HT1
DE60328735D1 (de) Chinazolinderivate
DE602004004553D1 (de) Chinazolinderivate
DE602004022180D1 (de) Chinazolinderivate
IS8439A (is) Nýjar kínólín afleiður
ATE395346T1 (de) Chinazolinderivate als tyrosinkinaseinhibitoren
NO20055649D0 (no) Substituert dihydrokinazolin med antiviale egenskaper
DE602005016890D1 (de) Chinolinderivate und ihre verwendung als mycobakterielle inhibitoren
ATE498613T1 (de) Chinazolinonderivate als parp-hemmer
DK1474420T3 (da) Quinazolinforbindelser
ATE446093T1 (de) Substituierte chinazolin-derivate als aurora- kinase inhibitoren
DK1453512T3 (da) Acetylenderivater med mGluR5 antagonistisk virkning
ATE413389T1 (de) Chinazolinderivate
ATE529421T1 (de) Chinolinderivate als phosphodiesterase-hemmer
ATE392897T1 (de) Chinolinderivate als npy antagonisten
ATE500227T1 (de) Amidderivate
ATE387451T1 (de) Chinazolinderivate als src- tyrosinkinaseinhibitoren
DE60324018D1 (de) Agonisten
DK1590351T3 (da) Fremgangsmåder til fremstilling af chinazolinalkaloider
SE0300124D0 (sv) Novel use of agonists and antagonist of hypothalamic receptors
IS8465A (is) Mótlyf af bradýkínín B1 viðtaka
DE60334703D1 (de) Heterocyclische derivate
FI20020420A7 (fi) Ulosottoelin
IS7870A (is) Tetrahýdrókínólín afleiður
IS2647B (is) Tetrahýdrókínólín afleiður